European Regulators Reject Vivus Obesity Drug Used In US

Law360, New York (October 19, 2012, 4:43 PM EDT) -- The European Medicines Agency on Thursday rejected Vivus Inc.’s application for approval of its Qsiva weight-control drug for human use, citing concerns about the drug’s long-term effects on patients’ heart and blood vessels, as well as their psychiatric and cognitive health.

Qsiva, a combination of weight-loss drug phentermine and seizure and migraine drug topiramate, was approved by the U.S. Food and Drug Administration in July and was recently launched in the U.S. under the trade name Qsymia.

The EMA’s Committee for Medicinal Products for Human Use...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.